KIR3DL2 may represent a novel therapeutic target in aggressive systemic peripheral T-cell lymphoma

Saved in:
Bibliographic Details
Published inHaematologica (Roma) Vol. 108; no. 10; pp. 2830 - 2836
Main Authors Decroos, Amandine, Cheminant, Morgane, Bruneau, Julie, Carras, Sylvain, Parinet, Vincent, Pelletier, Laura, Lacroix, Laetitia, Martin, Nadine, Giustiniani, Jérôme, Lhermitte, Ludovic, Asnafi, Vahid, Battistella, Maxime, Lemonnier, François, De Leval, Laurence, Sicard, Hélène, Bonnafous, Cécile, Gauthier, Laurent, Genestier, Laurent, Caruso, Stefano, Gaulard, Philippe, Hermine, Olivier, Ortonne, Nicolas
Format Journal Article
LanguageEnglish
Published Italy Ferrata Storti Foundation 11.05.2023
Fondazione Ferrata Storti
Subjects
Humans
Letter to the Editor
Life Sciences
Lymphoma, T-Cell, Cutaneous
Lymphoma, T-Cell, Peripheral
Receptors, KIR3DL2
Skin Neoplasms
Online AccessGet full text
ISSN0390-6078
1592-8721
1592-8721
DOI10.3324/haematol.2022.282220

Cover

More Information
Bibliography:content type line 23
SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
PMCID: PMC10542838
Disclosures
AD performed the ADCC experiments and part of the KIR3DL2 immunostaining (TENOMIC Cohort), participated in the analyses of KIR3DL2 promoter methylation, analyzed the data, and revised the paper. MC participated in the design of the study, KIR3DL2 immunostaining, analyzing of the data, and writing and revision of the paper. JB performed part of the KIR3DL2 immunostaining, analyzed the results, and revised the paper. LLh and VA performed and analyzed the results of the flow cytometry studies. MB participated in the interobserver correlation study on KIR3DL2 expression in FFPE samples. SC performed and analyzed the results of the flow cytometry studies (KIR3DL2 and KIR3DL1 on the CeVi cohort) and revised the paper. VP and LP designed the experiments and performed the analyses of KIR3DL2 promoter methylation. LLa and NM provided technical support for the KIR3DL2 staining by immunohistochemistry with the 5.133, MOG1-MK323-12B11, and MOG1l-P3-R4D-H5 mAb and LLa performed the double staining experiments by immunofluorescence for confocal imaging. JG provided technical support for the ADCC experiments. HS, CB, and LGa provided the specific antibodies to KIR3DL2 for the immunohistochemistry, flow cytometry, and ADCC experiments and participated in writing and revising the paper. LGe participated in the design of the study and in writing and revising the paper. SCa performed the statistical analysis regarding interobserver correlations on KIR3DL2 expression on FFPE samples. LdL reviewed PTCL included in the study. PG participated in the design of the study and writing and revising the paper. OH participated in the design of the study and writing and revising the paper. NO designed the study, analyzed the data, and wrote the paper.
HS, CB, VP, FG and LG are employees of Innate Pharma and Amandine Decroos received financial support from Innate Pharma for her PhD. HS, LG and CB are senior directors and have an ownership interest (including patents) in Innate Pharma. AD, MC, JB, NO, PG and OH received research grants from Innate Pharma. The other authors have no conflicts of interest to disclose.
Contributions
Data presented in this manuscript are available upon request.
Data-sharing statement
ISSN:0390-6078
1592-8721
1592-8721
DOI:10.3324/haematol.2022.282220